Connect with us

Business

Oracle’s sudden AI stardom is giving 1999 energy

Published

on


A version of this story appeared in CNN Business’ Nightcap newsletter. To get it in your inbox, sign up for free here.


New York
 — 

Oracle, a large but generally sleepy cloud-computing company, just had an absolutely bonkers day on Wall Street.

The stock (ORCL) shot up more than 40% Wednesday morning, its largest single-day jump ever. It was such big leap that it minted Oracle co-founder Larry Ellison $100 billion in less than hour, making him the world’s richest person and bumping Elon Musk to second place.

The catalyst wasn’t a flashy product rollout or a surprise earnings beat — in fact, Oracle’s quarterly revenue and profit came in below Wall Street’s expectations Tuesday evening.

Instead, the fire came from Oracle’s outlook for the next few years, which, if it pans out, would cement the company as a power player in artificial intelligence. That’s a big “if,” though — especially given that the bulk of Oracle’s rosy outlook hinges on revenue from one major customer, the unprofitable OpenAI, according to the Wall Street Journal.

Oracle’s outlook is “so exuberant that if we’d gotten this sort of prediction from a less established company it might have been shrugged off as either a lie or a misplaced digit,” Steve Sosnick, chief strategist at Interactive Brokers, told me.

Here are the key things powering Oracle’s stock at a clip it hasn’t experienced since the late-90s dot-com-bubble era, when it rose nearly 600% in the span of a year before falling back to earth by 2022:


  • Oracle’s CEO, Safra Catz, said the company’s cloud infrastructure revenue would grow 77% to $18 billion by the end of May 2026. But that’s not all: It projects that revenue to hit $144 billion by 2030.

  • Catz said Oracle had signed four multi-billion-dollar contracts with three different customers, giving the company $455 billion in “outstanding contract revenue” that it expects to collect on. That metric is up 359% from last year.

Oracle, which sells database software, has somewhat quietly ingratiated itself to investors in the AI gold rush this year by securing deals with AI companies hungry for computing capacity. (If semiconductor giant Nvidia (NVDA) is the “picks and shovels” play of the current frenzy, think of Oracle as the Levi Strauss play — it’s not mining the gold, just providing durable trousers.) And now it’s making its debut as a force to be reckoned with against rival cloud-storage providers like Google, Amazon and Microsoft.

If Oracle’s head-spinning projections seem too good to be true, well, that’s all part of the fun-house mirror effect of the generative AI bubble (yes, I said “bubble”). Because for any of Oracle’s future projections to make sense, its AI customers, including OpenAI, have to make, like, a lot of money — something the ChatGPT maker has shown no clear path to doing anytime soon. (The Information reported last week that OpenAI’s projected cash burn this year through 2029 will hit $115 billion — about $80 billion higher than the company previously expected.)

Like other big tech names, Oracle is betting much of its future on the promise that demand for computing capacity will keep going up as generative AI ushers in some kind of as-yet-undefined revolution. So tech companies are spending hundreds of billions of dollars to build out the data centers — giant, energy-sucking buildings full of computer servers — to ensure the US has the technical infrastructure to deliver all of the AI magic.

That gamble on infrastructure is so massive it actually eclipsed consumer spending this year as the main driver of GDP growth, according to Renaissance Macro Research.

“This data center buildout continues to be a major support to the US economy… so we of course hope that Larry Ellison is right and that this massive buildout is sustainable,” Peter Boockvar, chief investment officer of One Point BFG Wealth Partners, said in a note Wednesday.

But Boockvar also sounded a note of caution: “While Oracle just knocked the cover off the ball, when I see one day market cap increases of such epic proportions, I can’t not think of what I witnessed in 1999.”

(Ahem, 1999 being the start of the dot-com crash.)

Oracle’s capital expenditures are “truly extraordinary,” at $35 billion for this fiscal year, which is about 52% of revenue, Boockvar notes. In 2024, it was 13% of the company’s revenue. “We’ve never seen such capital intensity from these previously large-free-cash-flow-generating businesses.”

In other words, Oracle is a huge company, and it’s never spent money like this ever before.

The risk here, of course, is that Oracle’s big customer, OpenAI, doesn’t deliver.

Generative AI, the engine of ChatGPT, is one of those rare technologies that manages to get less marketable over time. The more many regular people encounter AI in their lives, the more they come to associate it with “slop” on their Facebook feeds. Chatbots cannot reliably respond to human beings’ queries, and they have a pesky tendency of dragging said humans into delusional, at times deadly, mental spirals.

It isn’t completely useless, to be sure, but AI’s proponents have had an extremely difficult time building an application that’s lived up to their own hype (nor, certainly, has any of it lived up to the lofty valuations propping up American tech companies).

Without a game-changing tech update that either drastically lowers its costs or dramatically boosts its profits, OpenAI may be toast. And that presents a systemic risk to not just Oracle, in particular, but to the tech sector more broadly.

If Oracle can stick the landing, Sosnick said, “then by all means, this rally is well-deserved.”

“Yet you are correct in pointing out the risks inherent in the market’s complete revaluation of Oracle… Not only are Oracle stockholders crucially dependent upon the company meeting its guidance, but the broader market is, too.”





Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

AstraZeneca pauses £200m Cambridge investment

Published

on


Mitchell LabiakBusiness reporter and

Simon JackBusiness editor

Getty Images Pharmaceutical company Astrazeneca's logo on the side of an office building with dark opaque windows. There is a grey sky behind the building.Getty Images

AstraZeneca has paused plans to invest £200m at a Cambridge research site in a fresh blow to the UK pharmaceutical industry.

The project, which was set to create 1,000 jobs, was announced in March 2024 by the previous government alongside another project in Liverpool, which was shelved in January.

Friday’s announcement comes after US pharmaceutical giant Merck scrapped a £1bn UK expansion, blaming a lack of government investment, and as President Donald Trump pressures pharmaceutical firms to invest more in the US.

An AstraZeneca spokesperson said: “We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused.”

Over the last 10 years, UK spending on medicines has fallen from 15% of the NHS budget to 9%, while the rest of the developed world spends between 14% and 20%.

Meanwhile, pharmaceutical companies have been looking to invest in the US following Trump’s threats of sky-high tariffs on drug imports.

In July, AstraZeneca said it would invest $50bn (£36.9bn) in the US on “medicines manufacturing and R&D [research and development]”.

Earlier this week Merck, which had already begun construction on a site in London’s King’s Cross which was due to be completed by 2027, said it no longer planned to occupy it.

The multi-national business, known as MSD in Europe, said it would move its life sciences research to the US and cut UK jobs, blaming successive governments for undervaluing innovative medicines.

Getty Images A close up of Pascal Soriot, chief executive officer of AstraZeneca Plc, speaking into a microphone during a signing ceremony event in Washington, DC in July where he was announcing the firm's $50bn investment in the US. He is wearing a dark suit and a white shirt and a US flag is in soft focus behind him.Getty Images

AstraZeneca boss Pascal Soriot announced the firm’s $50bn investment in the US in July

AstraZeneca’s announcement on Friday means none of the £650m UK investment trumpeted by the last government will currently happen.

The paused Cambridge project would have been an expansion of its existing Discovery Centre, which already hosts 2,300 researchers and scientists.

The stoppage comes after it scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Merseyside in January, blaming a reduction in government support.

It said at the time that after “protracted” talks, a number of factors influenced the move, including “the timing and reduction of the final offer compared to the previous government’s proposal”.

Successive UK governments have pointed to life sciences as one of its most successful industries.

Former chancellor Jeremy sector said the sector was “crucial for the country’s health, wealth and resilience” while Chancellor Rachel Reeves said AstraZeneca was one of the UK’s “great companies” days before it scrapped its Liverpool expansion.



Source link

Continue Reading

Business

CBA, NAB and other big banks building AI agents as business banking competition heats up

Published

on


Major lenders are building artificial intelligence-powered “agents” – software that can do the same work as humans – in their business banking divisions, as the battle for AI supremacy in financial services intensifies despite workforce concerns about the risk to jobs.

Commonwealth Bank of Australia is building what it describes as “virtual relationship managers” in its business bank. The customer-facing technology is in a pilot stage as the bank discusses the timing of a market rollout with regulators.

Loading…



Source link

Continue Reading

Business

AI Is Automating Technical Skills. Here Are the Soft Skills You Need.

Published

on


If hard skills are increasingly being automated, employers are shifting focus to what AI can’t replicate: creativity, empathy, critical thinking, and other essential soft skills.

For years, technical abilities were king, but the tide may be turning.

Indeed’s Hiring Lab took a look at job postings and analyzed which soft skills were listed. The top were communication, leadership, and organizational prowess. Forty-three percent of all job listings had at least one soft skill advertised.

Soft skills show up in job postings across industries, but maybe not where you’d expect:

In a world where machines can write code and analyze spreadsheets, the need for human insight, emotional intelligence, and creativity has never been more critical.

Employers don’t just want workers who can do the job; they want people who can collaborate, innovate, and lead.

Sign up for BI’s Tech Memo newsletter here. Reach out to me via email at abarr@businessinsider.com.





Source link

Continue Reading

Trending